The problem with antibody radiotheranostics is because of the large size of antibodies it takes around a week for them to fully penetrate into a tumour. This results in the patient being exposed to too much radiation and suffering lots of side-effects.
This is where the click-chemistry antibody technology that CU6 has really shines. You expose the patient to the non-radioactive click chemistry-labeled antibody a week before you add the theranostic-labeled small molecule. The radioactive small molecule can get into the tumour quickly and attach specifically to the antibody in situ in the tumour via the click chemistry reaction. It really is a very clever approach and once you have it working with one antibody you can scale it out to any antibody.
There is more about this technology in the CU6 announcement from last year.
https://hotcopper.com.au/threads/an...ibody-pre-targeting-with-ip-from-msk.7512943/
CU6 - Media and Industry News, page-153
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.12 |
Change
0.140(2.81%) |
Mkt cap ! $1.595B | |||
| Open | High | Low | Value | Volume |
| $4.91 | $5.15 | $4.90 | $4.563M | 903.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4640 | $5.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.13 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |